Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds
Rhea-AI Summary
Mangoceuticals (NASDAQ: MGRX) filed a PCT international application (P-641039-PC) on February 26, 2026 to seek global patent protection for its antiviral animal feed and drinking water additive technology that powers MGX-0024.
The filing claims priority to U.S. provisional 63/763,785 (Feb 26, 2025), extends protection to 150+ countries, and cites zero respiratory mortality in 29,000 commercial birds plus significant prophylactic benefit versus H5N1 in a controlled challenge study. U.S. protection remains under Patent No. 11,517,523 with national patents granted or pending in major jurisdictions.
Positive
- PCT filing (P-641039-PC) extends IP reach to 150+ countries
- Field trials reported zero respiratory-related mortality across 29,000 birds
- Controlled study showed statistically significant prophylactic benefit against H5N1
- U.S. patent protection maintained under Patent No. 11,517,523
- Corresponding national patents granted or pending in EU, Canada, China, India, Australia, Japan
Negative
- None.
Market Reaction – MGRX
Following this news, MGRX has gained 35.09%, reflecting a significant positive market reaction. Argus tracked a peak move of +34.9% during the session. Our momentum scanner has triggered 18 alerts so far, indicating notable trading interest and price volatility. The stock is currently trading at $0.50. This price movement has added approximately $2M to the company's valuation.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.
Key Figures
Market Reality Check
Peers on Argus
Pre-news, MGRX was down 2.95% while key health-information peers showed a mix of modest gains and losses, and momentum names like BFRG and ACON were up. This points to stock-specific dynamics rather than a broad sector move.
Previous Acquisition Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 19 | Patent acquisition | Positive | +1.6% | Acquisition of mushroom-derived wellness patent to expand product pipeline. |
| Jun 04 | Patent allowance | Positive | +6.9% | Japanese patent allowance for preventive infection technology from Intramont. |
| Apr 25 | Portfolio acquisition | Positive | +3.4% | Acquisition of a global patent portfolio for preventive care solutions. |
Acquisition- and IP-related announcements have historically seen modestly positive next-day moves, suggesting the market often reacts constructively to Mangoceuticals’ patent and portfolio expansion updates.
Over the past year, Mangoceuticals has repeatedly used acquisitions to build an IP-backed wellness and preventive-care platform. On Apr 25, 2024 it acquired a global preventive-care patent portfolio, followed by a Japan patent notice on Jun 4, 2024 tied to that technology. On Dec 19, 2024 it added a mushroom-based wellness patent targeting a large functional-mushroom market. Today’s PCT filing for MGX-0024 continues this IP-consolidation trajectory around antiviral and preventive solutions.
Historical Comparison
In the past year, MGRX logged 3 acquisition/IP expansion headlines, averaging a 3.96% next-day move. Today’s PCT patent filing fits this pattern of leveraging IP to support new product platforms.
Acquisition activity progressed from a broad preventive-care portfolio to specific regional patent allowances and mushroom-based wellness IP, now extending into global PCT coverage for antiviral MGX-0024 technology.
Market Pulse Summary
The stock is surging +35.1% following this news. A strong positive reaction aligns with Mangoceuticals’ history of constructive responses to acquisition and IP-expansion news, where prior deals showed average moves near 3.96%. The PCT filing reinforces global protection around MGX-0024 after earlier efficacy data on 29,000 birds. Investors would need to weigh this growing patent moat against the company’s small market cap of $6.24M and past capital-raising activity when assessing durability.
Key Terms
prophylactic medical
intellectual property regulatory
patent application regulatory
AI-generated analysis. Not financial advice.
Dallas, TX, March 06, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, and a pioneer in innovative wellness solutions and its partner IntraMont Technologies, Inc. today announced the filing of a Patent Cooperation Treaty (PCT) international application (P-641039-PC) on February 26, 2026, to secure broad global patent protection for the antiviral animal feed and drinking water additive technology that powers MGX-0024.
This PCT filing directly extends the intellectual property portfolio supporting the results highlighted in the February 23, 2026 press release, including zero respiratory-related mortality across 29,000 birds in commercial field trials and statistically significant prophylactic benefit against highly pathogenic H5N1 in the ICAR-NIHSAD controlled challenge study.
The application, titled “ANTIVIRAL ANIMAL FEED OR DRINKING WATER ADDITIVE AND METHODS FOR INHIBITING RESPIRATORY OR ORALLY ACQUIRED VIRUS INFECTION IN ANIMALS OR BIRDS THEREWITH,” claims priority to U.S. Provisional Patent Application No. 63/763,785 filed February 26, 2025. It enables pursuit of patent protection in over 150 countries through a single streamlined process.
“Filing the PCT application just days after releasing our compelling efficacy data underscores our commitment to rapidly securing worldwide IP rights for this innovative, non-antibiotic solution,” said Jacob Cohen, CEO of Mangoceuticals, Inc. “We are now positioned to protect and commercialize MGX-0024 on a global scale for distributors, farms, and agencies in key markets like India and beyond.”
The technology remains protected in the U.S. under Patent No. 11,517,523, with corresponding national patents already granted or pending in the EU, Canada, China, India, Australia, and Japan.
Further details on the PCT filing and full study reports are available at www.MangoRxIPHoldings.com.
About Mangoceuticals, Inc.
MangoRx is focused on developing a variety of men’s health and wellness products and services via a secure telemedicine platform. To date, the Company currently offers pharmaceutical-based products specifically related to the treatments of erectile dysfunction, hair growth, hormone replacement therapies, and weight management. Interested consumers can use MangoRx’s telemedicine platform for a smooth experience. Prescription requests will be reviewed by a licensed medical provider and, if approved, fulfilled and discreetly shipped through MangoRx’s partner compounding pharmacy and right to the patient’s doorstep. To learn more about MangoRx’s mission and other products, please visit www.MangoRx.com.
Cautionary Note Regarding Forward-Looking Statements
Certain statements made in this press release contain forward-looking information within the meaning of applicable securities laws, including within the meaning of the Private Securities Litigation Reform Act of 1995 (“forward-looking statements”). These forward-looking statements represent the Company’s current expectations or beliefs concerning future events and can generally be identified using statements that include words such as “estimate,” “expects,” “project,” “believe,” “anticipate,” “intend,” “plan,” “foresee,” “forecast,” “likely,” “will,” “target” “up to” or similar words or phrases. These forward-looking statements include, but are not limited to, the review and evaluation of strategic transactions and their impact on shareholder value; the process by which the Company engages in evaluation of strategic transactions; the outcome of potential future strategic transactions and the terms thereof; macroeconomic, industry and market conditions, including inflation, interest rate volatility, recessionary trends, financial market disruptions, changes in regulatory or political environments, and other factors beyond the Company’s control that could adversely affect its business, financial condition and results of operations; our ability to meet the continued listing requirements of Nasdaq and maintain the listing of our common stock on Nasdaq, including as a result of our current non-compliance with certain listing standards relating to our stock price; our ability to successfully undertake a crypto treasury strategy in the future; risks related to the significant number of shares in the public float, our share volume, the effect of sales of a significant number of shares in the marketplace; dilution caused by offerings; conversion of outstanding shares of preferred stock and the rights and preferences thereof, the fact that we have a significant number of outstanding warrants to purchase shares of common stock and other convertible securities, the resale of which underlying shares have been registered under the Securities Act of 1933, as amended, dilution caused by exercises/conversions thereof, overhang related thereto, and decreases in the trading price of our common stock caused by sales thereof; our ability to build and maintain our brands; cybersecurity, information systems, fraud and website risks; compliance with applicable laws and regulations affecting our operations, products, marketing, manufacturing, labeling and distribution; shipping, production and supply chain delays; reliance on third parties for prescribing, compounding and other key services; product safety risks; macroeconomic and geopolitical conditions, including inflation, interest rates, recessions, pandemics, acts of war, tariffs and trade disruptions; protection of intellectual property; our ability to attract and retain key personnel; potential stock overhang and volatility in the trading price of our common stock; and consumer sentiment and discretionary spending trends. Although we believe that our plans, intentions and expectations reflected in or suggested by the forward-looking statements we make in this release are reasonable, we provide no assurance that these plans, intentions or expectations will be achieved. Consequently, you should not consider any such list to be a complete set of all potential risks and uncertainties.
More information on potential factors that could affect the Company’s financial results is included from time to time in the “Cautionary Note Regarding Forward-Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s filings with the SEC, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, and subsequent reports. These filings are available at www.sec.gov and at our website at https://www.mangoceuticals.com/sec-filings . All subsequent written and oral forward-looking statements attributable to the Company or any person acting on behalf of the Company are expressly qualified in their entirety by the cautionary statements referenced above. Other unknown or unpredictable factors also could have material adverse effects on the Company’s future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and takes no obligation to update or correct information prepared by third parties that are not paid for by the Company. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.
FOR INVESTOR RELATIONS
Mangoceuticals Investor Relations
Email: investors@mangorx.com
FAQ
What did Mangoceuticals (MGRX) file on February 26, 2026?
What efficacy results support the MGX-0024 PCT filing by MGRX?
Does Mangoceuticals (MGRX) already have U.S. patent protection for MGX-0024?
How does the PCT filing affect Mangoceuticals' (MGRX) commercialization plans?
Where can investors find more information on the MGX-0024 PCT filing and study reports?
